Speaker Faculty

• David Azad, Managing Director, Galen Partners
• John Baldoni, SVP, Platform Technology & Science, GlaxoSmithKline Pharmaceuticals R&D
• David Bar-Shalom, Professor, University of Copenhagen
• Debra Bingham, Partner, Valeo Partners
• Woody Bryan, PhD, Vice President, Business Development and Project Management, Supernus Pharmaceuticals
• Steven Burrill, CEO, Burrill & Assoc.
• Samuele Butera, VP and Head, Biosimilars North America, Sandoz, Inc
• Susan Cady, Director, Formulation Development, Merial
• Mahesh Chaubel, Director, Global R&D, Baxter
• David Cipolla, Senior Director, Pharmaceutical Sciences R&D, Aradigm Corporation
• Brian Cooley, Director, Drug Delivery New Product Planning, Eli Lilly
• Brigitte Cron-Eckhardt, Manager, Drug Delivery, Novartis Animal Health
• Michael Cucolo, Director, Strategy, Alliances and Transactions, Bristol Myers Squibb
• Weiguo Dai, Research Fellow, Drug Delivery and Device Development, Johnson & Johnson Pharmaceutical R&D
• Michael DesJardin, SVP Product Development, Jazz Pharmaceuticals
• Michael Flakus, Director, Worldwide Business Development, Pfizer
• Eric Galia, PhD Project Director Global Preclinical R&D International Technical Alliance Manager, Grünenthal Innovation
• Danchen Gao, Director, Intellectual Property Strategy, Abbott Laboratories
• Paul Gellert, Senior Principal Scientist, ASTRAZENECA
• Matthew J. Golden, Legal Director, Patents, Merck & Co., Inc.
• Philip Green, Senior Director, Drug Delivery Devices, Merck Bioventures
• David Haase, Senior Manager, Device Development, Genentech Inc
• Chris Halliday, Partner, Morgan, Lewis & Bockius LLP
• Scott Henry, Head, Healthcare Research, Senior Research Analyst, ROTH Capital Partners
• Beth Hill, PhD, Global Development Director, Drug Delivery and Device Development Technologies, Janssen
• Geoffrey Hird, Principle Scientist, Drug Delivery Tech Drug Delivery Technology, Parenteral Product Development, Eisai Inc
• Keith Horspool, Vice President Pharmaceutics, Boehringer Ingelheim
• James Ingebrand, Vice President and General Manager, 3M Drug Delivery Systems
• Jan Jezek, CSO, ARECOR
• Peter R Joiner, CEO, Madeira Therapeutics
• Chris Jones, Vice President and Global Head, Pharmaceutical Development, AstraZeneca
• Robert Jones, CEO, Acura Pharmaceuticals
• Michael Kaufman, VP, Formulation Science, Millennium Pharmaceuticals
• Jack Kelly, VP Strategic Marketing, Unilife
• Suzanne Kiani, Associate Director, CMC Regulatory Affairs, MedImmune
• Susan Koppy, Senior Vice President, Business Development, Aslan Pharmaceuticals
• Marc Koska, OBE, Inventor and Philanthropist
• Tomas Land, Director, Strategy and Sourcing, Diabetes Research Unit, Novo Nordisk
• Lee Leichter, President, P/L Biomedical
• John Liu, Senior Director, Reimbursement Strategy, Astellas Pharma
• Bill Martin, Group VP, Business Development, Accredo Health
• John Masiz Esq., President and CEO, Biochemics
• Mark McClellan, Director, Engleberg Center for Healthcare Reform
• Karen McGregor, R&D Platform Director, Catalent Pharma Solutions
• Dave Mead, Director, Business Development, Novozymes Biopharma UK Ltd
• Nadav Navon, PhD, VP, R&D, IntecPharma
• Sesha Neervannan, Vice President, Pharmaceutical Development, Allergan Inc
• Dennis Nelson, CSO, Chattem, Inc, a Sanofi Company
• Bob Nissen, President, Nissen Consulting Group, LLC
• Dan Palmer,CSO, Q-Chip Ltd.
  
• Riccardo Panicucci, Global Head Chemical & Pharmaceutical Profiling, Novartis
• Tim Patrick, President and CEO, Carticept
• Harvinder Popli, Director, In-Licensing, Ranbaxy Labs, Ltd
• Julia Rashba-Step, Senior Director, Novel Delivery Technologies, Pfizer Biotherapeutics Research & Development
• Andy Rensink, President and COO, Tapemark
• Graham Reynolds, VP, Marketing & Innovation, West Pharmaceutical Services
• Joel Richard, Vice President, Drug Product Development, Ipsen
• Jonathan Rigby, CEO, SteadyMed Ltd.
• Sven Rohmann, CBO, Pantec Biosolutions
  
• Krishnan Sampath, PhD, Associate Director, Biologics Formulation & Drug Process Development, Hospira
• Jay Schrier, Senior Director, Pharmaceutical Development, Pacira Pharmaceuticals
  
• Christopher Seaton, Senior Vice President, Global Licensing, Bayer Pharmaceuticals
• Vik Seoni, Senior Vice President, Corporate Development, Orapharma, Inc.
• Jeff Shimizu, Chief Technology Officer, Medimetrics
• Lee Shorter, GlaxoSmithKline Pharmaceuticals
• Bobby Singh, VP, Research & Development, Corium
• Ronald Smith, PhD, Executive Director and Head Product Value Enhancements, Merck & Co
• David Steinberg, Managing Director, Deutsche Bank
• Lior Stram, Director, Technology Management, Flextronics Medical
• Philip Strassburger, VP & Intellectual Property Counsel, Purdue Pharma LP
• Anand Subramony, PhD, Principal Fellow & Head, Novel Delivery Technologies & Therapeutics (NDT), Novartis Institutes for BioMedical Research, Inc.
• Rajneesh Taneja, Director, Pharmaceutical Development, Takeda Pharmaceuticals North America
• Mark Tomai, Director, Head, TRL and MTS Business Development
• Li-Chun Tsou, Biologic Project Lead, Global Pharmaceutical Commercialization Technologies, Merck, Sharp & Dohme Corp.
• Uros Urleb, Chief Scientific Officer, Sandoz International GmbH
• Peter Wickersham, SVP, Cost of Care,Prime Therapeutics
  
• Brian Windsor, SVP, Portfolio Management, Emergent Technologies
• Brian Winger, Director, Preformulation, Eli Lilly
• Jeffrey Wolfson, Partner, Haynesboone
• Brett Zbar, Partner, Aisling Capital
• Alex Zisson, Partner, Thomas McNerney & Partners